Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

42
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
42
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

34
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
34
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

40
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
40
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

62
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
62
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

35
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
35
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

69
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
69

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apparent End-Stage Heart Failure Forced Toward a Successful Myocardial Recovery.

JACC. Case reports·2025
Same author

Antiarrhythmic properties of ranolazine: A review of the current evidence.

International journal of cardiology·2015
Same author

Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.

Hypertension (Dallas, Tex. : 1979)·2015
Same author

Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension.

Circulation·2015
Same author

Lipids, blood pressure and kidney update 2014.

Pharmacological research·2015
Same author

Regional variation in the incidence and outcomes of in-hospital cardiac arrest in the United States.

Circulation·2015

Related Experiment Video

Updated: Sep 20, 2025

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.0K

Recovery From Left Ventricular Dysfunction.

Basha Behrman1, Wilbert S Aronow2,3, William H Frishman2,3

  • 1From the Department of Medicine, Westchester Medical Center, Valhalla, NY.

Cardiology in Review
|June 8, 2022
PubMed
Summary

Patients with heart failure with recovered ejection fraction (EF) have better outcomes but still require ongoing treatment. Continued guideline-directed medical therapy and monitoring are recommended to prevent adverse cardiac events.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K
Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
07:11

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography

Published on: October 28, 2020

3.0K

Related Experiment Videos

Last Updated: Sep 20, 2025

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
08:19

Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs

Published on: July 12, 2022

3.0K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.4K
Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography
07:11

Morphological and Functional Assessment of the Right Ventricle Using 3D Echocardiography

Published on: October 28, 2020

3.0K

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • Heart failure treatment has advanced, leading to a growing population of patients with normalized ejection fraction (EF).
  • These patients, termed heart failure with recovered EF, show improved mortality compared to those with persistently reduced EF.

Purpose of the Study:

  • To define the unique characteristics and prognosis of heart failure with recovered EF.
  • To explore the implications of recovered EF on long-term cardiac health and management strategies.

Main Methods:

  • Review of studies on the natural history of patients with improved EF.
  • Analysis of prognostic divergence between recovered and persistently reduced EF groups.
  • Examination of molecular and histologic changes in recovered EF patients.

Main Results:

  • Each 5% increase in left ventricular EF correlates with a 4.9-fold decrease in mortality odds.
  • Despite improved EF, patients retain some molecular/histologic changes associated with heart failure with reduced EF (HFrEF).
  • Patients remain at risk for functional decline and adverse cardiac events, especially if therapy is discontinued.

Conclusions:

  • Heart failure with recovered EF is a distinct diagnosis requiring specific management.
  • Guidelines recommend indefinite continuation of guideline-directed medical therapy for these patients.
  • Surveillance echocardiography is advised to monitor left ventricular function and prevent adverse events.